PA3-17 Injection Treatment of Adult Patients With CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies

NCT05170568 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

22

Enrollment

INDUSTRY

Sponsor class

Conditions

CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies

Interventions

BIOLOGICAL: T cell injection targeting CD7 chimeric antigen receptor

Sponsor

PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]